Tags

Type your tag names separated by a space and hit enter

Prevention of rotavirus disease: guidelines for use of rotavirus vaccine.
Pediatrics 2007; 119(1):171-82Ped

Abstract

On February 3, 2006, a bovine-based pentavalent rotavirus vaccine (RotaTeq, Merck & Co Inc, Whitehouse Station, NJ) was licensed by the US Food and Drug Administration for use in infants in the United States. The American Academy of Pediatrics recommends routine immunization of infants with 3 doses of pentavalent rotavirus vaccine administered orally at 2, 4, and 6 months of age. The first dose should be administered between 6 and 12 weeks of age; immunization should not be initiated for infants older than 12 weeks of age. Subsequent doses should be administered at 4- to 10-week intervals, and all 3 doses of vaccine should be administered by 32 weeks of age. Pentavalent rotavirus vaccine can be coadministered with other childhood vaccines. Pentavalent rotavirus vaccine is contraindicated for infants with a serious allergic reaction to any vaccine component or to a previous dose of vaccine.

Pub Type(s)

Clinical Trial, Phase III
Journal Article
Practice Guideline

Language

eng

PubMed ID

17200286

Citation

American Academy of Pediatrics Committee on Infectious Diseases. "Prevention of Rotavirus Disease: Guidelines for Use of Rotavirus Vaccine." Pediatrics, vol. 119, no. 1, 2007, pp. 171-82.
American Academy of Pediatrics Committee on Infectious Diseases. Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. Pediatrics. 2007;119(1):171-82.
American Academy of Pediatrics Committee on Infectious Diseases. (2007). Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. Pediatrics, 119(1), pp. 171-82.
American Academy of Pediatrics Committee on Infectious Diseases. Prevention of Rotavirus Disease: Guidelines for Use of Rotavirus Vaccine. Pediatrics. 2007;119(1):171-82. PubMed PMID: 17200286.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. A1 - ,, PY - 2007/1/4/pubmed PY - 2007/1/31/medline PY - 2007/1/4/entrez SP - 171 EP - 82 JF - Pediatrics JO - Pediatrics VL - 119 IS - 1 N2 - On February 3, 2006, a bovine-based pentavalent rotavirus vaccine (RotaTeq, Merck & Co Inc, Whitehouse Station, NJ) was licensed by the US Food and Drug Administration for use in infants in the United States. The American Academy of Pediatrics recommends routine immunization of infants with 3 doses of pentavalent rotavirus vaccine administered orally at 2, 4, and 6 months of age. The first dose should be administered between 6 and 12 weeks of age; immunization should not be initiated for infants older than 12 weeks of age. Subsequent doses should be administered at 4- to 10-week intervals, and all 3 doses of vaccine should be administered by 32 weeks of age. Pentavalent rotavirus vaccine can be coadministered with other childhood vaccines. Pentavalent rotavirus vaccine is contraindicated for infants with a serious allergic reaction to any vaccine component or to a previous dose of vaccine. SN - 1098-4275 UR - https://www.unboundmedicine.com/medline/citation/17200286/Prevention_of_rotavirus_disease:_guidelines_for_use_of_rotavirus_vaccine_ DB - PRIME DP - Unbound Medicine ER -